Clark Estates Inc. NY Cuts Stock Position in Bausch + Lomb Co. (NYSE:BLCO)

Clark Estates Inc. NY lessened its holdings in Bausch + Lomb Co. (NYSE:BLCO) by 12.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 600,000 shares of the company’s stock after selling 87,500 shares during the quarter. Bausch + Lomb accounts for 2.1% of Clark Estates Inc. NY’s investment portfolio, making the stock its 12th biggest position. Clark Estates Inc. NY’s holdings in Bausch + Lomb were worth $10,836,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Charles Schwab Investment Management Inc. boosted its position in shares of Bausch + Lomb by 38.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 41,085 shares of the company’s stock worth $742,000 after purchasing an additional 11,330 shares in the last quarter. Alberta Investment Management Corp boosted its holdings in shares of Bausch + Lomb by 36.0% in the fourth quarter. Alberta Investment Management Corp now owns 3,008,193 shares of the company’s stock worth $54,328,000 after buying an additional 796,400 shares during the last quarter. Blue Trust Inc. raised its holdings in Bausch + Lomb by 68.3% in the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company’s stock worth $48,000 after purchasing an additional 1,004 shares during the period. Renaissance Capital LLC grew its stake in shares of Bausch + Lomb by 116.2% during the 4th quarter. Renaissance Capital LLC now owns 94,182 shares of the company’s stock valued at $1,701,000 after acquiring an additional 50,622 shares during the period. Finally, Ellsworth Advisors LLC bought a new position in shares of Bausch + Lomb in the fourth quarter worth approximately $665,000. Institutional investors own 11.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on BLCO shares. Stifel Nicolaus reduced their price target on shares of Bausch + Lomb from $19.00 to $18.00 and set a “hold” rating on the stock in a report on Wednesday, January 29th. Needham & Company LLC reissued a “hold” rating on shares of Bausch + Lomb in a research note on Thursday, February 20th. Citigroup cut shares of Bausch + Lomb from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $24.00 to $22.00 in a research report on Wednesday, December 11th. Royal Bank of Canada decreased their price target on shares of Bausch + Lomb from $22.00 to $18.00 and set an “outperform” rating for the company in a research report on Thursday, February 20th. Finally, Wells Fargo & Company dropped their target price on Bausch + Lomb from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Thursday, January 16th. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Bausch + Lomb presently has a consensus rating of “Hold” and an average target price of $20.00.

Bausch + Lomb Stock Performance

Shares of BLCO opened at $15.87 on Wednesday. Bausch + Lomb Co. has a 12-month low of $13.16 and a 12-month high of $21.69. The firm has a market cap of $5.59 billion, a PE ratio of -17.43, a price-to-earnings-growth ratio of 0.85 and a beta of 0.46. The company’s 50 day simple moving average is $17.04 and its 200-day simple moving average is $18.18. The company has a current ratio of 1.60, a quick ratio of 1.01 and a debt-to-equity ratio of 0.72.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings data on Wednesday, February 19th. The company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.02. The business had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.26 billion. Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. The company’s revenue was up 9.1% on a year-over-year basis. During the same period last year, the company posted $0.24 EPS. As a group, equities analysts predict that Bausch + Lomb Co. will post 0.74 EPS for the current year.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.